MAP2K7 and melanoma: In line with the effects of BRAF inhibitor monotherapy discussed above, the combination of a BRAF inhibitor and a MEK inhibitor has been shown to increase immune-stimulatory molecules/cytokines [35], reduce immunosuppressive cytokines [35,36,37], reduce VEGF expression [36], increase T-cell infiltrates [37], increase HLA 1 [35] and melanoma antigen [37] expression, and increase markers of T-cell cytotoxicity [37] in BRAF-mutant melanoma.